Feraheme orange book patents?

What are the Orange Book Patents for Feraheme?

Feraheme, also known as ferumoxytol, is an injectable iron replacement therapy used to treat iron deficiency anemia in adult patients with chronic kidney disease. As a prescription medication, its market exclusivity is subject to regulation by the US FDA.

When Will Feraheme's Exclusivity End?

The patent for Feraheme's original formulation expired in April 2014, but new formulations can be patented under Orange Book listings. These listings are for formulations, methods of use, and dosing regimens that maintain market exclusivity under patent law.

What is on the Orange Book Patents for Feraheme?

According to DrugPatentWatch.com, there are currently Orange Book listings for Feraheme with multiple patent extensions. Some notable entries for Feraheme's Orange Book listings include [1], [2], with patents set to expire in 2030.

How Will Expiring Patents Affect Feraheme Market Exclusivity?

The expiration of Feraheme's Orange Book patents may lead to increased competition from generic or biosimilar manufacturers as soon as possible. According to DrugPatentWatch.com, several companies have announced plans to develop generic versions of Feraheme after the exclusivity period ends.

What are the Possible Implications for Patients?

Upon the expiry of Feraheme's patents, generic versions of the medication may become more widely available, offering potential cost savings and easier access to treatment for patients with iron deficiency anemia.